Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time
- 1 September 1993
- journal article
- research article
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 4 (9) , 809-818
- https://doi.org/10.1097/00019501-199309000-00008
Abstract
A synthetic RGD-containing cyclic peptide, TP9201, specific for the platelet αIIbβ3 receptor complex, was tested for its ability to accelerate thrombolysis and prevent reocclusion in experimentally induced coronary artery thrombosis. Anesthetized, open-chest dogs with occlusive thrombi received tissue plasminogen activator with TP9201 (113μg/kg bolus; 2.7ng/kg/min infusion, n = 7) or saline control (n = 9). A 2.8-fold increase in the duration of vessel patency from 52.7 ± 63.7 min to 149.1 ± 63.7 min (PConclusions TP9201 may be an effective therapy for the prevention of re-thrombosis after thrombolytic therapy without adversely affecting hemostasis.Keywords
This publication has 0 references indexed in Scilit: